Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Telitacicept in CTD-ILD
NCT07495033Phase 3Not yet recruiting
- Sponsor
- RemeGen
- Start
- Apr 2026
- Primary completion
- May 2029
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 3 trial of telitacicept in Connective tissue disease-associated interstitial lung disease (CTD-ILD), sponsored by RemeGen. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
telitacicept
03
Conditions
Connective tissue disease-associated interstitial lung disease (CTD-ILD)
Beyond the preview
Go deeper on NCT07495033.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07495033.